



Delivery of cancer therapeutics to extracellular and intracellular targets: Determinants, barriers, challenges and opportunities☆



Jessie L.-S. Au^{a,b,c,d,*}, Bertrand Z. Yeung^b, Michael G. Wientjes^a, Ze Lu^a, M. Guillaume Wientjes^a

^a Optimum Therapeutics LLC, 1815 Aston Avenue, Carlsbad, CA 92008, USA

^b Department of Pharmaceutical Sciences, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73014, USA

^c Medical University of South Carolina, Charleston, SC 29425, USA

^d Taipei Medical University, Taipei, Taiwan, ROC

ARTICLE INFO

Article history:

Received 18 September 2015

Received in revised form 24 November 2015

Accepted 2 December 2015

Available online 11 December 2015

Keywords:

Computational modeling

Extracellular matrix

Immune checkpoint therapy

Interstitial and transvascular transport

Intracellular trafficking

Nanoparticles

Tumor microenvironment

Spatiokinetics

ABSTRACT

Advances in molecular medicine have led to identification of worthy cellular and molecular targets located in extracellular and intracellular compartments. Effectiveness of cancer therapeutics is limited in part by inadequate delivery and transport in tumor interstitium. Parts I and II of this report give an overview on the kinetic processes in delivering therapeutics to their intended targets, the transport barriers in tumor microenvironment and extracellular matrix (TME/ECM), and the experimental approaches to overcome such barriers. Part III discusses new concepts and findings concerning nanoparticle–biocorona complex, including the effects of TME/ECM. Part IV outlines the challenges in animal-to-human translation of cancer nanotherapeutics. Part V provides an overview of the background, current status, and the roles of TME/ECM in immune checkpoint inhibition therapy, the newest cancer treatment modality. Part VI outlines the development and use of multiscale computational modeling to capture the unavoidable tumor heterogeneities, the multiple nonlinear kinetic processes including interstitial and transvascular transport and interactions between cancer therapeutics and TME/ECM, in order to predict the *in vivo* tumor spatiokinetics of a therapeutic based on experimental *in vitro* biointerfacial interaction data. Part VII provides perspectives on translational research using quantitative systems pharmacology approaches.

© 2015 Elsevier B.V. All rights reserved.

Contents

1.	Introduction	281
2.	Part I. Delivery of cancer therapeutics from injection site to tumor interstitium	282
2.1.	Processes	282
2.1.1.	Tumor blood flow	282
2.1.2.	Extravasation	282
2.1.3.	Interstitial transport	282
2.1.4.	Tumor lymphatic drainage	283
2.2.	Approaches to improve delivery, interstitial transport and retention of therapeutics in solid tumors	283
2.2.1.	Enhance blood-to-tumor transport and extravasation	283
2.2.2.	Passive targeting via enhanced permeability and retention	283
2.3.	Unique issues for nanomedicines	283
2.3.1.	Effects of nanoparticle properties on blood-to-tumor transfer	283
2.3.2.	Approaches to enhance nanoparticle delivery to tumors	283
2.3.3.	Tumor priming to promote extravasation and interstitial transport	283

Abbreviations: Ago2, argonaute 2; CDE, clathrin-dependent endocytosis; CIE, clathrin-independent endocytosis; CPP, cell penetrating peptides; CTLA4, cytotoxic T-lymphocyte-associated antigen 4; ECM, extracellular matrix; EPR, enhanced permeability and retention; ERC, endosome recycling compartment; IFP, interstitial fluid pressure; ILV, intraluminal vesicle; MVB, multivesicular bodies; NP, nanoparticles; PD1, cytotoxic T cell programmed death-1 membrane receptor; PDL1 and PDL2, PD1 ligands; RES, reticuloendothelial system; RISC, RNA induced silencing complex; RNAi, RNA interference; siRNA, short interfering RNA; TME, tumor microenvironment.

☆ This review is part of the *Advanced Drug Delivery Reviews* theme issue on “Extracellular Matrix (ECM) and ECM-like materials: Therapeutic Tools and Targets in Cancer Treatment”.

* Corresponding author at: Optimum Therapeutics LLC, 1815 Aston Avenue, Carlsbad, CA 92008, USA. Tel.: +1 760 438 1155; fax: +1 760 438 1156.

E-mail address: jau@optimumtx.com (J.L.-S. Au).

3.	Part II. Delivery of cancer therapeutics to cellular and intracellular targets	284
3.1.	Cell surface binding	284
3.2.	Internalization	285
3.3.	Endocytic transport	285
3.3.1.	Endosomes	285
3.3.2.	Endocytic recycling	285
3.3.3.	Intracellular release	285
3.4.	Cytosol-to-nucleus translocation	285
3.5.	Unique issues for RNAi gene therapeutics	286
3.6.	Approaches to improve intracellular bioavailability.	286
3.6.1.	Promoting internalization	286
3.6.2.	Promoting intracellular release from endosomes/lysosomes	287
4.	Part III. Interactions of nanotherapeutics with tumor microenvironment and extracellular matrix	287
4.1.	Structure of nanoparticle biocorona	287
4.2.	Effect of biocorona on nanoparticle disposition	287
4.3.	Effect of biocorona on functionality of nanoparticle gene therapeutics	287
4.4.	Potential role of tumor microenvironment and extracellular matrix on biocorona formation and stability	287
4.5.	Perspectives	288
5.	Part IV. Animal-to-human translation of cancer nanotherapeutics	288
6.	Part V. Immune checkpoint therapy	289
6.1.	T cell immune therapy	289
6.2.	T cell immune checkpoint inhibitors	289
6.3.	Migration of activated cytotoxic T cells to reach tumor cells	289
6.3.1.	Trafficking of leukocytes to tissues	289
6.3.2.	Migration of leukocytes in tissue interstitium	291
6.3.3.	Barriers to T cell migration in tumors	292
6.4.	Tumor heterogeneity and specificity: role of tumor microenvironment and extracellular matrix	292
6.5.	Approaches to improve T cell infiltration in tumors	292
7.	Part VI. Computational approaches to interrogate and quantify the effects of tumor microenvironment and extracellular matrix	292
7.1.	Use of computational models to capture heterogeneities in tumor properties and therapeutics	292
7.2.	Models for drug/nanoparticle transport	293
7.3.	Predictive models of in vitro interstitial diffusive transport based on nanoparticle–cell interaction parameters	293
7.3.1.	Hypothesis and experimental systems	293
7.3.2.	Model assumptions and parameterization	293
7.3.3.	Experimental results and evaluation of model performance	293
7.3.4.	Model-simulations to interrogate the effects of NP properties on interstitial diffusive transport	293
7.4.	Multiscale models to capture tumor spatial heterogeneities and to predict in vivo spatiokinetics of therapeutics	294
7.4.1.	Hypothesis and experimental systems	295
7.4.2.	Model assumptions and parameterizations	295
7.4.3.	Experimental results and evaluation of model performance	295
7.4.4.	Model-simulations to interrogate the effects of intratumoral heterogeneities on spatiokinetics	295
8.	Part VII. Perspectives	296
	Acknowledgments	297
	References	297

1. Introduction

Advances in molecular genetics and medicine, nanotechnology and pharmaceutical sciences have broadened the scope of cancer therapeutic targets. In addition to tumor cells, components in the tumor microenvironment (TME) have emerged as clinically important targets. TME is a complex structure comprising cells, blood vessels, cytokines and extracellular matrix (ECM). The three major cell types in TME are fibroblasts, inflammatory/immune cells, and endothelial cells; these cells secrete or express cytokines and chemokines that interact with tumor cells [1]. ECM proteins, primarily collagen and fibronectin, are synthesized and deposited by fibroblasts, and represent a major fraction of larger tumors. Classes of cancer therapeutics include the traditional small molecules, macromolecules (e.g., proteins, antibodies), bioconjugates, viral vectors, and nanoparticle (NP) carriers (e.g., liposomes, micelles, and polymeric NP) [2]. These agents target tumor vasculature (e.g., anti-angiogenics), tumor interstitium (e.g., diagnostics or therapeutics targeting extracellular proteins), cell membrane (e.g., antibodies), and intracellular compartments such as the cytosol (e.g., RNAi, drugs targeting cytosolic proteins) [3–5] and nucleus (e.g., DNA gene vectors, DNA-active drugs) [6,7]. Their utility depends on their ability to reach their sites of action [8], which in turn

is partly determined by TME and ECM. The goals of this report are to outline the processes and determinants of the delivery, transport and residence of cancer therapeutics and their NP carriers in solid tumors. The unique challenges and opportunities for nanomedicines, RNAi gene therapeutics and immune checkpoint therapy are also discussed.

As most cancer therapeutics are administered by intravenous injections, this review will focus on the transfer from blood to target sites. For the orally active agents such as tyrosine kinase inhibitors, additional processes governing the transport into the systemic blood, including absorption from the gastrointestinal tract and hepatic first pass elimination, are additional considerations.

This review comprises seven parts. Part I outlines the transfer processes of cancer therapeutics from the injection site to tumor interstitium, and Part II the processes from interstitium to cellular and intracellular targets; the barriers for delivery and the approaches to overcome these barriers are summarized. Part III discusses the interactions of therapeutics with components of TME and ECM, e.g., formation of NP biocorona. Part IV outlines the challenges in animal-to-human translation of cancer nanotherapeutics. Part V is a review of immune checkpoint inhibitors, the newest therapeutic group with demonstrated clinical benefits in cancer patients, and a discussion of the potential roles of TME/ECM in determining their treatment

Download English Version:

<https://daneshyari.com/en/article/8402761>

Download Persian Version:

<https://daneshyari.com/article/8402761>

[Daneshyari.com](https://daneshyari.com)